GIFT
Graft engineering to improve allogeneic stem cell transplantation
| Coordinatore | KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 179˙588 € |
| EC contributo | 179˙588 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2007-4-2-IIF |
| Funding Scheme | MC-IIF |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-08-01 - 2010-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | coordinator | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Allogeneic stem cell transplantation (ASCT) is a curative therapy for various haematological malignancies. Obtaining suitably matched donors, problems with graft versus host disease (GVHD) and infection, however, limit the wider application of this therapy. Knowledge from previous studies has highlighted the need for a more effective and integrated approach to address these issues. This project examines how our knowledge of immune cell trafficking can be exploited in conjunction with haploidentical stem cell transplantation to minimise GVHD, promote immunity and antileukemic responses in ASCT. The knowledge derived from this study will contribute to a greater understanding of how immune cell trafficking can be utilised to improve ASCT and immunotherapies. Its success will lead to new and more effective protocols for the design and development of stem cell grafts for the treatment of cancer.'
Introduzione (Teaser)
Infection is a major problem following cell grafting; it accounts for some 30% to 40% of treatment-related mortality. This continues to limit the positive effects of treating malignancy with stem cell transplantation.
Descrizione progetto (Article)
Allogeneic stem cell transplantation (ASCT) is the transfer of blood-forming stem cells from a similar yet not necessarily related donor. Used as a treatment method for a variety of malignancies, challenges in finding well-matched donors, graft versus host disease (GVHD) and infection often limit its wider application.
The 'Graft engineering to improve allogeneic stem cell transplantation' (GIFT) project endeavoured to see how current knowledge of immune cell transfers can be exploited to minimise the incidence of GVHD, enhance immunity and stave off leukaemic responses in ASCT. A primary task was to investigate if FTY720, an immunosuppressive agent, can be used in donors in the phase of stem cell mobilisation to create a graft with low GVHD potential. At the same time it should offer good anti-tumour and immune rebuilding potential.
Study results showed that FTY720 can be successfully used in donors to selectively weaken certain cells and thus prevent GVHD following ASCT. This is effected without affecting cancer-fighting memory T cells or immune boosting natural killer cells. This means it is possible to improve the immunological features of peripheral blood stem cell grafts and therefore fight the threat of infections, avoid GVHD and even preserve anti-tumour activity.
It is expected that this study's findings will facilitate the design of new and more effective protocols guiding stem cell grafts for treating cancer.